Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
OMS control number.

Substitute for form 1449/PTO				Co	Complete if Known		
INFORMATION DISCLOSURE			OSURE	Application Number	10/790,943		
STATEMENT BY APPLICANT			LICANT	Filing Date	9/3/2002		
Date Submitted: May 20, 2009			20.2000	First Named Inventor	William Robert Wilson		
	Date Submitted, May 20, 2009			Art Unit	1614		
(use as many sheets as necessary)			necessary)	Examiner Name	James D. Anderson		
Sheet	1	of	1	Attorney Docket Number	093397-0501		

U.S. PATENT DOCUMENTS					
Examin er Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F25	WO 2009/053681	04-30-2009	Antisoma Research Limited		
		1			1	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1				
	D72	Ghaemmaghami, et al., "New Agents in the Treatment of Small Cell Lung Cancer", Chest, 113(1) Suppl.: 86S-91S (1998).			
	D73	Horsman, et al., "Improving Conventional Cancer Therapy by Targeting Tumour Vasculature", British Journal of Cancer, 80(2) Suppl.: 90 (1999) Abstract			
	D74	Siemann, et al., "Potentiation of Chemotherapy by Vascular Targeting Agents", British Journal of Cancer, 80(2) Suppl.: 90 (1999) Abstract			

_			
Examiner Signature	/James Anderson/	Date Considered	10/19/2009

FEXAMISE: Initial if reference considered, whether or not clation is in conformance with NFEP 603. Draw line through clation in froit in conformance and not considered include copy of this form with next communication to applicant. 1 Applicant's unique celebration designation number (optional), 2 See Notas Codes of USPTO Patent Documents at www.uspin.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanoperate obsciences, the including of the part of the region of the Emperor must precede the sential number of the patent document. 5 Nicol of document is 5 Nicol of document shapes appropriate symbols as indicated on the document under VIPIO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required to obtain or relatar to seefity by the public which for lead by the VIPIO is provided by ST.CR 13 or and 13.8. The information is required to obtain or relatar to seefity by the public which for lead by the USPTO to process) an application. Confidentiality is governed by 30 U.S.C. 122 and 37 CFR 1.14. This collection of individual case. Althought comments on the amount of patenting, propriating, and admining the completed application from the full STO. Time will vary dependently quote the individual case. Althought comments on the amount of the completed application of the other process. SEND TO. Commission of the Pratents, F.O. SEN 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commission for Pratents, F.O. SEN 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.